Abstract: The present invention relates to pharmaceutical compositions comprising heterocyclic diamidines and their use in the prophylaxis and/or treatment of diseases associated with fibrosis, in particular for the treatment of diseases such as systemic sclerosis (limited cutaneous scleroderma and diffuse cutaneous scleroderma), pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, chronic graft-versus-host disease, Crohn's disease, arthrofibrosis, myelofibrosis, Dupuytren's disease and nephrogenic systemic fibrosis and tumours selected from mamma carcinoma, endometrial adenocarcinoma, ovarian serous tumor, lung adenocarcinoma, lung squamous cell tumor, colorectal tumor and pancreatic tumor.

Abstract: The invention relates to an implant for replacing bone or cartilage material, which is constituted by a plurality of elements (B, B1, B2, B3, B4) produced from a non-metallic, linearly elastic material, an element (B, B1, B2, B3, B4) being connected to adjacent elements (B, B1, B2, B3, B4) by a viscoelastic polymer material such that gaps (L) remain between the adjacent elements (B, B1, B2, B3, B4) and that the adjacent elements (B, B1, B2, B3, B4) can move relative to one another.

Abstract: The present invention relates to pharmaceutical compositions comprising heterocyclic diamidines and their use in the prophylaxis and/or treatment of diseases associated with fibrosis, in particular for the treatment of diseases such as systemic sclerosis (limited cutaneous scleroderma and diffuse cutaneous scleroderma), pulmonary fibrosis, hepatic cirrhosis, renal fibrosis, chronic graft-versus-host disease, Crohn's disease, arthrofibrosis, myelofibrosis, Dupuytren's disease and nephrogenic systemic fibrosis and tumours selected from mamma carcinoma, endometrial adenocarcinoma, ovarian serous tumor, lung adenocarcinoma, lung squamous cell tumor, colorectal tumor and pancreatic tumor.

Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.

Abstract: The present invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from inflammatory disease to a treatment with a therapy against said inflammatory disease using brain imaging techniques. Furthermore, the present invention relates to a pharmaceutical composition comprising an active ingredient for the treatment of human subjects suffering from inflammatory disease and being identified as responders to therapy against the inflammatory disease according to the method of the invention. Preferably, this invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from rheumatoid arthritis to a treatment with TNF-antagonists comprising at least one step of brain imaging, preferably with an fMRI apparatus. The present invention shows that response to TNFi depends on the gestalt of brain activity in rheumatoid arthritis (RA) patients.

Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.

Abstract: The present invention relates to a method of determining whether a subject having or suspected of having inflammatory disease may potentially benefit from treatment with a p38 mitogen-activated protein kinase (p38MAPK) inhibitor, which method comprises (I) obtaining an inflammatory tissue sample from the subject; and (II) determining whether p38MAPK, in particular p38MAPK?, is expressed in the tissue sample. The present invention further relates to the use of an antibody against the p38MAPK protein for determining whether a subject having or suspected of having inflammatory disease may benefit from treatment with a p38 mitogen-activated protein kinase (p38MAPK) inhibitor; kits for determining from an inflammatory tissue sample whether a subject having or suspected of having inflammatory disease may benefit from treatment with a p38 mitogen-activated protein kinase (p38MAPK) inhibitor; and to the corresponding use of said kit.

Abstract: A switching apparatus includes a grounded, insulating gas-filled housing, the housing having a housing wall, and a power circuit-breaker disposed in the housing. The apparatus further includes a current connection for a first busbar, a current connection for a second busbar, and a current connection for a load outgoer. The apparatus further includes a grounding switch disposed in the housing, the grounding switch being connected between the power circuit-breaker and the current connection for the load outgoer, and a busbar disconnector, the busbar disconnector being connected between the current connection of the first busbar and the power circuit-breaker and between the current connection of the second busbar and the power circuit-breaker. An outwardly extended, first tubular flange arrangement is attached over a first opening in the housing wall, and an outwardly extended, second tubular flange arrangement is attached over a second opening in the housing wall.

Abstract: The reactor switch is provided for switching on and off a reactor (2) in a multiphase electrical high-voltage network. It has switch poles (3) which are arranged phase-by-phase between the reactor (2) and a part of the network containing, a high-voltage line (1). These switch poles (3) in each case contain at least two series-connected switching chambers (11, 12; 13, 14) in parallel with which at least two series-connected varistors (15, 16; 18, 19) are connected. This reactor switch is intended to be capable of disconnecting short-circuits occurring between the reactor switch and the reactor (2) without problems.